VTYX - Earnings call transcript Q1 2022 | Ventyx Biosciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and thank you for standing by. Welcome to the Ventyx Biosciences First Quarter 2022 Financial Results Conference Call. [Operator Instructions] I would now like to hand the conference over to your speaker today, Mr. Martin Auster. Please go ahead.

Marty Auster

operator. you, Thank everyone. Good afternoon, joining the for today. call Thanks webcast Welcome our discussing a update. and results to Biosciences conference business Ventyx we’ll first providing be and call quarter financial XXXX

be company’s the under tab of Events investor As at & Investor most News reminder, our website the presentation a can section. found the on www.ventyxbio.com, recent

that of webcast statements will we Raju, begin statements with completion Securities to please I about again current call expect the which with publicly forward-looking forward-looking opinions first file those today, Commission, CEO. our such or discussed our remind or statements as uncertainties trials, operations that, any & of including statements or could about no Exchange quarter our greater afternoon. Before enrollment contain over statements revisions are filings of and information new that results release to implied timing only or of clinical like Ventyx’s we go commencement, materially this events. to of everyone that are XXXX, the cash, forward-looking timeframe Factors timing the of Raju Founder company, hand of light differ from to cause including undertake future actual funding in Mohan, the note anticipated outcomes could marketable forward-looking we Form that securities. to to XX-Q to These will for this to I’d results call, in this statements and the these cash expressed Dr. by of equivalents ahead. obligation these the in revise detail results and With and for conference of call cause trial reflect and clinical the the the risks actual and date release expected subject data Please differ.

Raju Mohan

to afternoon. thanks joining our everyone and Marty, Thanks, for call this

to then and financial a start highlights. agenda. we briefly by open update a before Q&A. the the brief discussion company’s pipeline, to hand for of and call through followed quarter call with the Marty our business present back me run then an first results conference the let recent going We’ll of overview So, the overview I’m for

Before I to minute Chief and announced and formally take news we Bill President Officer. week, Ventyx want as to earlier begin, however, a leadership we introduce this joined the his team Medical Sandborn,

been the you inflammatory diseases, field a accomplished the inflammatory approved of many development clinician a the and or of both biologics know, the As and bowel a Bill particularly molecules. is renowned number and in space, of in immunology expert closely autoimmune involved space, Bill has of disease small highly IBD. in in I&I therapies

the new As immune-mediated shaping importantly his advance target for strategy, us to developing multiple Chairman as our team as our clinical few a years, role development Bill Board both past but our Clinical of key and a our He diseases. as the [ph] role we in team clinical Advisory will played portfolio lead in now and President, has for CMO. more

with appreciate move of I’d a would if team, we you few to welcome So Bill. words the Bill? the agenda. before ahead Ventyx say the rest

Bill Sandborn

Thank good you and Raju, welcome, for everyone. warm so afternoon, much, the

medical of now the an team’s foremost it’s medicines, immune-mediated most clinic. Ventyx of – been innovative five the including in have arthritis, I psoriasis, I’m that time the the of by Raju the dedicating our and joining needs full believe VTXXXX, and disrupt be products candidates And forward of to strongly Board. to closely X call over coming dominated to differentiated past inhibitor details the our to and now potential look for is allosteric oral are program the in year. markets, currently which thrilled best-in-class attention progress important important an turn the I’ve my TYKX to Phase and quarter Ventyx Chair clinical with this biologics. our that third portfolio to as our update unmet back sharing which I treatment psoriatic the lupus. years, I’ll program worked Raju. for on of the immunology Over Advisory more months, early large the three with team and address Crohn’s in disease including Clinical potential VTXXXX remarkable adviser diseases, see to

Raju Mohan

and Bill, to welcome again, Thanks, once team. the

and pipeline the to move now a update. I’ll So, business

our TYKX, of continued both I’m terms sharing targeting proud look efforts, a was really quarter Bill number and over a updates, we NLRPX. for continue really months. period of all of XXXX in said, key with of you three advance important first the the and as SXPX forward next us, programs and So clinical team’s we to to execution few as our

now, for these milestones. each upcoming and progress to So including recent I’d briefly address like of programs,

we let So for JAK highly selective its shows no me TYKX. inhibition all our VTXXXX allosteric of earlier, profile begin preclinical that have on other disclosed TYKX measurable VTXXXX, novel inhibitor. with is isoforms. It Based

these clear, So pushing safety potential been to just VTXXXX a ICXX with to target, TYKX-driven ICXX tolerability window to and from that achieve up very targets. outset, best-in-class inhibitor our highly wide levels, a the TYKX levels with selective clinical cover not develop has that allows for goal exposure but us allosteric TYKX

best-in-class potentially design pathways, to the XXX back virtually for the cytokines, the work such of and others. JAKX repeat, this be highly really molecule has to and or interferon-alpha, pathways, that our demonstrated eliciting any preclinical TYKX, who inhibition achieving I again, pathways of IL-XX key target other TYKX particular, in pathways, comes and key built IL-X, as allosteric domain VTXXXX chemistry our XXX, of selective call our to IL-XX, JAK to JAKX inhibits I IL-XX, and craftsman, profile no So detectable as such no, IL-XX what while

these will JAK findings laboratory clinical avoiding JAK seen with this including associated pathways with are VTXXXX that JAK-mediated dose dermatological been we pathways other exposures inhibitors, tolerability that either to allow believe and or safety has and AEs. So adverse us issues high and profile with while

dose So a and is trial higher a significantly to trial escalated healthy dose with volunteers. began we we doses, up Phase completed doses. This subtherapeutic last X cohorts. low seven for at year, We doses, in single-ascending VTXXXX

As that saw, stated very we before, results engagement. PD the both terms we what have we PK drug the pharmacodynamic in what exposure, of call these we and call with are pleased on target – we PK effects,

dose part five also Our Phase our is the multiple MAD which has our trial, multiple-ascending dose – trial, X of Phase trial X called cohorts.

exposures. complete of end dosing data at dose doses a again, X Phase second of range, quarter therapeutic by plan dose begin level is and the a escalate we We the around to in expected early the QX. low much and higher end and the Here, that update provide to

show data time program from to is engagement. and Our characterizing our data target safety our X plan at and Phase also exposure full this levels

oral data data, formulation our selected In will or trial. solid dose also present we we on that expect in our these addition to tablet Phase X

with of indications, efficacy coverage As to an expect profile trials half followed we oral second our with have Phase the to and terms for superior potentially safety, we in target target of the us and seen We in agent psoriasis, all biologics. may of beginning commence previously efficacy allow guided, to believe VTXXXX by XXXX, exposure closer in Crohn’s arthritis that X achieve the disease. psoriatic

biologics, a disease indications by this also and believe large these annual may psoriatic to and TYKX share psoriatic into including billion in expand in benefit. require markets, to billion including there’s within all market and Crohn’s disease. currently TYKX these including may market psoriasis for new $X arthritis, $XX areas which to billion-plus a disease, psoriasis, markets, addition arthritis other a Crohn’s very $XX utility opportunity a of market dominated like as a in higher achieve safe capture annual the is beyond profile reminder, validation, annual believe lupus. exposures an which therapeutic We particular, And oral therapies are significant a in effective We

VTXXXX, is for in currently ulcerative SXPX modulator, UC. novel colitis moderate-to-severe or Next our X Phase receptor development

has is modulator. has This and for validated believe the rapid best-in-class mechanism, selectivity we compound profile another potentially high SXPXR has So the of clinically suppression robust characteristics this and of and and VTXXXX a all SXPXR metabolites, circulating minimizes titration first-dose effectively known also effective in this on-target known volunteers, important biomarkers, PD healthy active that Phase as in that effects used rate case, X lymphocytes we heart no regimen in bradycardia. and

reduction for range, us Our dose as Phase trial to clinical achievement I again, trials efficacy which wide safety is to a range PD X remission to before, This absolute with dose mentioned dose been exposures activity, and push shown the effect put to lymphocyte of PD and explored UC allowing demonstrated including outcomes, has key counts. in or previous correlate in pharmacodynamic maximize excellent broad dose as maximize with a VTXXXX placebo-controlled fourth is for drug trial as an well XXX the tolerability we enroll other X a planned Phase SXPX patients, trial drugs. around In of This VTXXXX, our XXXX, quarter moderate-to-severe XXX in the randomized, two followed to SXPX open-label point, weeks period. initiated UC patients. primary includes a by dose open-label cohort XX clinical XX-week with time endpoint as active treatment patients the placebo efficacy as group at well remission VTXXXX the of extension clinical of

tolerability. efficacy other also and with measures, We evaluating safety be will along numerous

and enrollment designed on UC. specific on this forward look we have by of line the required first trial to We Phase top agency in the trial to we pivotal XXXX. as plan as for status updates data program serve Phase progresses, two Finally, registration induction in X trials the potentially the announcing to more X this

systemic inhibitor VTXXXXX, rheumatological which restricted NLRPX diseases. target to selective to as renal and I’ll inflammatory inhibitor, hepatic, beginning and profile, NLRPX our cardiovascular, designed diseases such Finally, peripherally with our turn is

of clinical exciting brain-penetrant, our selective year, the is like or brain-penetrant, proof which plan by – addition quarter For to the and line compound, of CNS to advance volunteers. summary more safety SAD/MAD this X of half which has This last dosing, this with we probability molecule, well a to end trials we one also QX, to DC that VTXXXXX data as as is year. in into another will of this I’d recently mention as inhibitor, VTXXXXX, disclosed time. in development of or and details at portfolio, fourth top trial CNS mechanism NLRPX the trials be additional report a details later target expect We to engagement. a in proof-of-concept, ongoing Phase a second on healthy include VTXXXXX, trial potent nominated completed and

novel It early exposure So chemical preclinical a XXXX-series. and good VTXXXXX shows different from studies. the penetration scaffold, good CNS is CNS in peripheral

this the The have quarter the at a ALS. which discovery fourth We advanced plan studies our the program, inhibitor VTXXXXX for markets, challenging. in first potential into inhibitors IND at we year candidates accessing NLRPX craftsman, this and clinic fourth be by the chemistry high advanced neurodegenerative on file Alzheimer’s the in been conditions, what the XXXX. remain to providing led neuro-inflammatory as of that has the truly in of pace discovery range discovery unmet brain-penetrant significant IND-enabling including VTXXXXX is achievement continues Scientific with believe program brain-penetrant We John – forward here our Officer, for Chief active a could very VTXXXXX address NLRPX of Ventyx, to future now of John’s to CNS-penetrant, updates Parkinson’s new to disease, historically target quarters. truly I and our is efforts large with very group Nuss that CNS-penetrant enter in to need look called team, quarter our and

set XXXX transformative is summary, to a year be in Ventyx. for So

a Phase VTXXXX an and X start, half year, number the inhibitor XXXX VTXXXXX for Our VTXXXX, trials filing second three end. potential of execution team Phase great for line top is later data initiating trials continued a data QX, in we on of line Phase for to X milestones by top remainder look of VTXXXX, the and X X the in over TYKX our off year’s early in including Phase for for forward the QX, IND to year,

own owned compounds So, Ventyx. I’d wholly discovered. by like is XXX% commercial our and to rights IP pipeline all our emphasize all and all internally that all to We rights

our for a Before call to we Auster discussion hand of to like financial I’d brief Q&A, results. back Marty? the to move Marty

Marty Auster

for financial the for quarter of here Thank the the I’ll our first expenses R&D summarize quarter quarter you, were million XXXX. million XXXX. results in $XX.X compared in $XX.X briefly Raju. first to

in-process Ventyx’s of first subsidiaries. related R&D The expense Oppilan XXXX Zomagen noncash the a did quarter million $XX.X to include acquisition and expense R&D

of and million in first the of was in for expenses of VTXXXX R&D XXXX XXXX for the first of as three second G&A over to net to loss half that first trend compared for Raju $X.X first trials XXXX, Phase launch expect upwards quarter $X.X to previously quarter $XX.X expenses quarter and $XX.X XXXX. prepare XXXX quarter the detailed. We were year the the million X we generally compared in the million million of

and the XXXX, for Importantly, cash, Phase well the X our this VTXXXX Phase Operator? for believe call, for the can of up to key call our marketable XXXX. Q&A pipeline, session, X I including across first afternoon’s fund sufficient remarks we cash Raju where colitis are the the Bill. be readouts the We provide psoriasis equivalent and for to operator million which prepared of were joined turn $XXX.X readouts back stage to report I’ll That believe into equivalents XX, with we both this marketable the and as readout to VTXXXX, securities ability concludes by cash expect open ulcerative and our in March to proof-of-concept us now and half XXXX. cash and securities current flow deliver may of operations clinical

Operator

first Sandler. [Operator from Yasmeen Piper of comes Instructions] Rahimi question Our

line Your is open.

Yasmeen Rahimi

my and you thrilled excited onboard, two for Good questions for to If you. I with Dr. have afternoon and and thank welcome taking Sandborn, may, I you. work questions.

as the recently have space than etrasimod question published. abstract you some in why maintenance decided second ongoing? activities The is significantly at then responses on the the was you placebo other be to a the were first light the certain am why you of it could phase. aware, many And the this decision Ventyx? I was you Ventyx Phase And in join that junction? tough lower induction on And one pause if is, shed might to X

be study closely. thoughts I some you you would And what mitigating placebo response, be? the again, X on So, with have and doing that could is Ventyx during to hear reasons regard in and maybe love their thrilled induction to for especially period? what onboard to the And working Phase

Bill Sandborn

Well, thank you questions. for the

As there And will Krueger for small to I’m about a in and the just Ventyx? years biologics I worked molecules. years. progress and Raju in prepared from these I’ve mentioned First, seeing why five the that with remarks, molecules have been with involved and Chris John persuaded be coming I transition

sort and then We’re the see best-in-class. be rheumatology that disease think space. And seeing happen we joining potential SXPX progressively of bowel the very best-in-class, and and follow-ons first-generation will I be And dermatology, inflammatory that are what the my that across the molecules molecules, chemistry Ventyx the group much both me great a view, modulator really and TYKX with have a great and to interested team. along discovery from

just XX-week differently. fully the With was induction would it. in join. being yet an Essentially, week a by etrasimod, there treat have presented. there as was interpret said was to to reported in trial weeks this rate presented so a happy can’t respect that the less straight mid-teens. the trial, So placebo think, slightly the was Week, higher talk XX%. data And I XX-week rate shorter much Digestive then through. But where probably Disease little we And be not other less placebo two too analysts about what was at a than They’ll some been you than I trial

much The it’s in that single also a placebo in maintenance. it’s So XX-week placebo XX-week trial lower in the not rate the rate digits. so was

variations So effect in have that trials, this on placebo in rates. that shows large there be can conduct that just multicenter

the mixture show that of biologic clinical trials aiming qualify really closest drug team all right entry and say, committed close a really gives endoscopy team to trial monitoring Ventyx biologic for naive of chance an the at development all details, of all into and just a exclusion for experience to what that up little the with hands-on it’s and And paying the getting takes patients, patients, doing closely details to well really mixture executing attention reading so criteria. them, of moderate adequately best collaboration of and our and that the development just central CROs to severe powered at those add without right the patients, The interpretable is would to and centers, I experience efficacy. on

Yasmeen Rahimi

the jump I’ll in Sandborn. Dr. back you, queue. Thank

Operator

from next our And ISI. Evercore of comes question Schimmer Josh

Your line open. is

Josh Schimmer

question. Good. Thanks taking for the

For there have commercialization time and one? optimal Thank own? to thought each Or stage your consider through you about clinical ones are advancing programs, of the each you that the on you. partner would to

Raju Mohan

Josh. Thanks, Good question. Yes.

commented remarks, at in financial plan. So prepared current of his that $XXX cash as Marty first primarily a We’re right? half over strong in currently XXXX with operating million position in extent into

the meaningful across our data regarding arthritis, kicking trials and with driving lupus disease psoriatic psoriasis, committed off. clinical TYKX X generate a XXX, to to we’re lead pipeline efficacy Crohn’s expect even and drug asset, obviously Phase possibly proof-of-concept So value across with the

you talked before right? from our second laser-focused is about of XXXX the data the As I think this and right XXXX, proof-of-concept So in our is know, of half in goal the executing we trials. expected back psoriasis now on

We’re POC compounds. rights terms well reach to future, commercial through all readouts. key of own capitalized we the And our really in

to as And across have we of so the number move a portfolio. flexibility have the our generate including value best to we’ll forward options, partnering

lot lucky to So proof-of-concept key keep do a meaningful capitalized that of here, be are – position that keep right? so. executing, in optionality we is but generating a So the to truly to we’re data really

Josh Schimmer

you. Thank it. Got

Raju Mohan

Yes, thanks Josh.

Operator

Michael next of question Yee our comes from And Jefferies.

open. is line Your

Michael Yee

the the Hey dosing you were Phase said in When guys for questions. questions, spoke both We to thanks the X. had very you you for and last, update up thanks related TYKX. two nicely

targets or out to up think to IL-XX, differentiation, just possibly with neutropenia and you going past X? that’s to things is about the and expectations I your how the show respect of I specifically three the well. And acne cohorts safety said ask a including for IL-XX wanted were and coverage related part which tolerability four or And second IBD. of you hopefully, you question Phase much had like extremely could on in important differentiation are in of you think five,

coverage what will Phase there us of have and X? draw be Thank higher specifically type you from relative those able to doses Stelara remind the Just we and at to stuff the like conclusions you.

Raju Mohan

Great, think each for call. sort I tied other. again, Mike. are And Thanks thanks of questions and on two to the the being

in look, and covering And so of where specifics terms are ICXX we of terms ICXX tuned. stay in of

data forward disclosing in this to looking early We’re QX.

the so we going where are just And to back trial. in

molecule, pathways, TYKX of and you shared that this dosing to evidence IL-XX not ICXX. hope of we but thesis the coverage exposures, exposures. of to recently have just Hopefully, And on built in cover a cohorts maximize endgame we of is sort final Again, part part interferon-alpha. this allow the continue The these cohorts, the I to if provide better in and maximized be key. it you goal MAD you obviously five can you as us the the exposures, trust we lupus, right? with of to to we non-clinically And in say which we window that that do of will tolerated. are if we hope our And have extremely gained demonstrate profile profile exciting exposures, it, we escalate this then we’re So call, the with really would reach our exposures. QD to is MAD IL-XX, do throughout target have and to So after so here. these only well trial dose is is is safety our for have can ICXX, cycle. compound more safety first, And

sharing will forward quarter. folks So in that with from hours third X Phase and again total early XX out more, that our readout to we’re XX, looking or bear

Michael Yee

we on remind and like comment higher conclusions relative potency it if relates IL-XX And stuff Stelara? your draw And the that as can can on us to you to doses? just at IL-XX,

Raju Mohan

Yes.

whole have – to profile What IL-XX, is hope I to believe And disclosed IL-XX comparable interferon-alpha, think ICXXs, numbers. hope should cover maximize Stelara, the bar you in really numbers; of again, And ICXX those and we we for a We be as have molecule our largest, is. think to safety to blood of and us. they’re low talked coverage. coverage of or this high IL-XX We the pretty the human by reach that we about, ICXXs, including we very ICXX us allow efficacy coverage numbers. IL-XX

then we’re to again, the just Crohn’s We’re with to each sharing targeting indications, of for lupus. here early psoriatic forward interferon-alpha for looking not for XQ. individual an the ICXX achieve the focus respective in ICXX, IL-XX/XX arthritis and is the efficacy But to but targets for and folks disease comparable biologics, psoriasis, disease

Michael Yee

guys. it. Got Thank you

Raju Mohan

Yes, thanks Mike.

Operator

comes question Credit Fauth next Suisse. Tiago our And from of

open. is line Your

Tiago Fauth

Hey, thanks question. for taking the

side. risk study portion hone interest, on manifestation curious the exposure basically, in profile those your you’re the perhaps path how of this to So going we’re the it forward? on in is and of a the for bit molecule, to use up, Just usually given in Thank seeing early dose the the more little have safety drugs of how I’m interpret how from safety be going terms the the the to will for informative how multi-ascending what to inform profile the you. and AE class? of other come

Raju Mohan

Thanks, Tiago. Great question. Yes.

we again, So you published there for and some more there’s the is out than data a deucravacitinib data of there. obviously other for molecules there to guide lot

reveal which lab such are such as themselves neutropenia, acne, within AEs, at. clearly dose abnormalities, skin looking period, generally is XX-day rash, findings, So period we a as urticaria, the

findings deucrava deucrava again, some themselves, detailed have the as stuff So that if of five the of has outcomes. period newer and you day within out the disclosed in revealed to come early particular look sometimes emphasize some has in have of these across shown drugs, and the case AEs XX-day with as

these cover MAD so program targets. looking mentioned again, our I maximizing at as with, exposures is before XX-day new dosing this So to cycle

other this dosing at in hand, On have careful the really So what on of look some drugs high period. other exposures. hand, one shown

no the other compound some and in show built then these careful were of have no I’ll to ground a assays show activity, on confident up allosteric compounds, have are But, build a molecule hint very these effects a if back functional again, at in been that where not zero, profile to of really we again, our to in see molecule, JAK selective and up. that, signaling, the of they period, we we look XX-day defer non-clinical very profile. relevant JAKX So safety of from that this would top

and the So the with our take Phase safety And so we at other without X have into profile trials non-clinical are of are the managed first, avoid some to for the a now, TYKX with just signals folks selective confident molecular is we seen. activity those effects going that we profile layered molecule, this look JAKX as mentioned that with that can of have that we that other hope that some to VTXXXX. you avoid not seen as you’ve inhibitors careful

Tiago Fauth

Thank helpful. so very Okay, much. you

Raju Mohan

thanks Tiago. Yes,

Operator

our next Sam LifeSci from of question And Slutsky comes Capital.

Your is open. line

Oliver McCammon

effect Oliver in you have NLRPX questions. as with Sam PD on be for we and is its pharmacodynamic I Slutsky. two for a think is markers taking known I is how to McCammon of these your but VTXXXXX, we And effect? appreciate filling initial this start, an most inhibitor, clinical it focused Hi, benefit? the clinical see about assessing markers data assays much should what to necessary

Raju Mohan

Yes.

these let I’ll markers A there’s Certainly, the on looking standard well. other NLRPX, just factors been for some we’ll not and SAA, IL-Xbeta, of these that serum for have some some disclosed be markets marker, general. this, as in amyloid also pathways of such Serum but as – So associated Bill with biomarkers at but

I’ll terms what compound Bill But plan of at Bill? sort proof engagement. comment So let target is long-term and at these of mechanism and careful – the look of we’ll more near-term look our XXXX. NLRPX with in on

Bill Sandborn

Yes, to not add. much

things a I think erythrocyte protein markers, old then sedimentation the more But rate. you’ve and simple like picked out there’s although mechanism-specific is some C-reactive SAA generic. the of standby little

of the all giving various study. more of as for degree them the proof but of trial half of Phase mechanism forward program looking in some biomarkers, have indication Raju So the view of we at of that proof look relevant, we’ll said been the certainly And the prepared well. the those mechanism of X holistic the used a development remarks, range are year, for for the the are to those to second during as be markers in we’re in indications. that that And

Oliver McCammon

That’s alone? as follow-up, of helpful. a sense be NLRPX to compared to quick it also then inhibiting very And potential would helpful get the blockade benefits IL-X a of beta

Raju Mohan

saying just IL-X Again, [indiscernible] a and pathologies is of the just a Yes. kind [indiscernible] are more come lead not as is storm, off effect has beta, pronounced results of cytokine a out. on you lot I’ll of sort by it NLRPX – that know, of mini doses some

in inhibiting So simply not IL-X inhibiting right? You’re [indiscernible] beta, you’re it’s doses, IL-XX.

sort beyond the but IL-X goes to it will Bill? So classic color Bill add biologic, of seen with perhaps the our beta and results this. we’ve more

Bill Sandborn

IL-X inhibition, it with you in IL-XX, the the spectrum Well, doesn’t or would full whether it that inhibition that goes I goes antagonist an like something it do [indiscernible]. there’s of beyond sense say sense or of a but antibody it less receptor have the in

labeled into of So look gout where have the sort recall and and the antagonism the benefit and to you’ll IL-X history at the around IL-X stuff like risk and of inhibitors receptor the inhibition IL-X warnings hypothesis played – you that broad all infection, has have a more things that limited same that and of and not may has more risk have. the the of the And we acceptability where risk the have NLRPX indications. will acting coverage the infection narrow various and of spectrum have an IL-XX

Oliver McCammon

you. Thank appreciate time. I the

Bill Sandborn

Oliver. Thanks,

Operator

And from our Oppenheimer. question of Jones Jeff next comes

line is open. Your

Jeff Jones

call. the guys Thank taking you you. Appreciate

well think been covered. pretty have I TYKX the

obviously, be light SXP results recent back that. for at other data soon that’s another efficacy and program SXP SXP mind? the to for that step out this the their In Thanks. the in to to on and or your space, the Bio Connect data DDW What of there, full does moment. out as the take etrasimod So I’ll well the market’s to of data be it to Phase it program stand the measures as reaction X

Raju Mohan

Yes. Thanks.

So let me the pick start expert course, out, up. here let and of

particular, effective X So bit for And our of let his the in the validation talked to compound, drug, SXPX for a on places drugs data, the and this SXPX ozanimod, positively right? this safe the from launch etrasimod, Pfizer continue our for with pharma which class of So of from differentiate to on on etrasimod, of and to really ozanimod safety. Bill? it VTXXXX, with Bill – a the particular, of the Arena efficacy But so over in thoughts UC about of and scenario good again and deal. has in disclosure the recently, is approval the the from hand me pharma we just first potential our build really this. perspective, value both a is perspective, most Phase more

Bill Sandborn

if history of we coming drugs metabolites at of sclerosis with products long generation this beginning then colitis, multiple earlier very had into half-life. in phosphorylated Well, look the ulcerative and the class

So something eight about of phosphorylated the instance, quickly metabolites ozanimod like days. for administered of becomes have half-life XX% that a

So a And biologic. a means it’s that onset. essentially slow it’s

is course stop If for off lymphocyte And or reduction, you the the course, a time when of look rate it of similarly you more. drug, slow. at doesn’t the plateau month

drug the of what’s profile? the range in a half-life ideal It’s So short XX hours.

need so. in drop a phosphorylated And come a metabolites, full the lymphocyte can stop half-life, then you has you Our quickly. to week it, get XX-hour no you if off the count or within product

so plateauing that gets that’s higher your important, a a see titration a dose Phase just reduction final to able not And dose but X. do not the of to and kind to really to right dose larger want during quite a you’re inflection I dose that choose linear plateau to think at point. You that find response, necessarily lymphocyte push of

larger in how with X to selected set switch Phase what can examples So achieve, you disease Phase slippage achieved seen our because maximizes and titration trials lymphocyte you there X backs see reduction that’s X final from the that you lymphocyte that you’re much between terms is, you dose some out X and sure Phase as was of into giving, in and really were really that. reduction some the that of you often away with dose from the volunteers healthy that Phase

the and meticulous other of believe have we forward will So dose trials, very to you count off with an setting, been really a solidly onset said well-powered I about a disease I dose the the the highest want adequately harkens reduce think we’ve back lymphocyte trial. in clinical regimen rate. the that taking fast thoughtful earlier, just what thing, then dose And titration fast conduct the

If which you patients, example think Asian about less in sort gave, expected particular bio-naive and that pharmacokinetics disease smaller response the you patients, heavily the heavily trial of background. of ethnic know we the

lot inconsistency trial And that the contribute so the of a results. there issues could design of were to

about. that if second-generation of drugs of talked just attention this Although effective to showed the the in we an the and need you reiterates think to really molecules I that is still differentiated want trial therapy class that all with colitis. just it ulcerative And effect, solidly pay effect, dose a totality a aspects you

Jeff Jones

Thank that. you for

Operator

questions. remarks. And I I’m showing no further closing for back to turn conference would Mohan like to the now Raju

Raju Mohan

Great. you all. Again, thank

in updates the We’re we’ve we in as about each connecting forward future. are guided where to And you with look look again, forward really sharing the appropriate to near folks time. excited programs, with you these clinical of

So Thanks, team. thank all. you

Operator

you call. for This today’s participating. concludes conference Thank

disconnect. now may You

Ventyx Biosciences (VTYX) 13 May 222022 Q1 Earnings call transcript